Although the VMAPRTLFL peptide derived from HLA-G in GBM cells has highest affinity for CD94/NKG2C reported so far [23], it is conceivable that competing peptides, such as those derived from classical HLA, can also be presented via HLA-E and therefore can modulate the cytotoxic response of NKG2C+ NK cells. The gene discussed is KLRC2; the disease is glioblastoma.